Germany’s planned statutory health insurance stabilisation bill has moved from cabinet proposal into parliamentary scrutiny, taking the medicines-pricing measures covered in earlier articles into a more formal stage of political and stakeholder review.
The Federal Ministry of Health (Bundesministerium für Gesundheit, BMG) records the first Bundestag reading and first Bundesrat passage of the GKV-Beitragssatzstabilisierungsgesetz (GKV Contribution Rate Stabilisation Act) on 12 June 2026, following the Federal Cabinet decision of 29 April.
The Government continues to frame the bill against projected statutory health insurance deficits. BMG puts the expected gap at €15.3 billion in 2027, rising to around €40 billion by 2030, and presents the bill as part of a short-term effort to bring expenditure growth closer to contribution-income growth.
The medicine measures remain those set out in the cabinet draft. They include a dynamic manufacturer discount for patent-protected medicines, rebate contracts for therapeutically comparable patent-protected medicine groups, price-volume rules and removal of two contested 2022 AMNOG-era controls.
The June development is that the package has entered committee-level scrutiny. At the Bundestag Health Committee hearing on 22 June, associations and experts set out their positions on the wider bill, with the medicine provisions remaining one of the main access-facing areas of attention.
The Federal Association of the Pharmaceutical Industry (Bundesverband der Pharmazeutischen Industrie, BPI) argued that the package would affect price formation, investment conditions, supply security and Germany’s position as a pharmaceutical location. The Association of Research-Based Pharmaceutical Companies (Verband Forschender Arzneimittelhersteller, vfa) warned that the measures would weaken the evidence-based AMNOG model and make access to innovative therapies more difficult.
Reuters reported on 15 June, citing an unnamed government source, that the variable discount mechanism would be replaced by fixed discounts. BMG did not confirm the point, saying that parliamentary deliberations were continuing.
The bill has therefore entered a more detailed negotiation phase. Even if the dynamic element changes during the legislative process, the central access question remains how far Germany intends to extend payer leverage before loss of exclusivity, and what that would mean for pricing predictability, AMNOG negotiation incentives and prescribing behaviour for patent-protected medicines.
Source: Federal Ministry of Health; German Bundestag
Link: GKV-Beitragssatzstabilisierungsgesetz (GKV Contribution Rate Stabilisation Act); Heftige Kritik von Fachverbänden an GKV-Sparpaket (Strong criticism from professional associations of the GKV savings package)
Date: 12 June 2026 and 22 June 2026
